comparemela.com

Page 2 - Connien Hess News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

Analysis Appears to Debunk Paclitaxel-Coated Device Risk in PAD

VOYAGER-PAD finds no excess mortality or amputation risk with paclitaxel-coated devices When a 2018 meta-analysis of 28 trials reported "a significant relationship" between exposure to paclitaxel via a drug-eluting stent used to treat peripheral artery disease (PAD) and excess mortality, the FDA responded by first issuing a warning letter, followed by a second letter urging

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.